Effect of visual retraining on visual loss following cortical damage
NCT ID NCT06121219
First seen Sep 10, 2026 · Last updated Sep 10, 2026
Summary
This project is intended to collect data using standard clinical tests and psychophysics to quantify the effect of visual cortical damage on the structure of the residual visual system, visual perception, spatial awareness, and brain function. The investigators will also assess the effect of intensive visual retraining on the residual visual system, processing of visual information and the use of such information in real-world situations following damage. This research is intended to improve our understanding of the consequences of permanent visual system damage in humans, of methods that can be used to reverse visual loss, and of brain mechanisms by which visual recovery is achieved.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 100 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Sep 2024
- Expected to finish
-
Jan 2032
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
21 to 80 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Cortically Blind Subjects Inclusion: * Between 21 and 80 years of age * Residents of the United States or Canada * Unilateral stroke or stroke-like damage to primary visual cortex or its immediate afferent white matter sustained within the specified age range (21-75 years) * Reliable visual field defects in both eyes as measured by Humphrey, MAIA, Goldmann, and/or equivalent perimetry, large enough to enclose a 5-deg diameter visual stimulus. * Able to fixate on visual targets reliably for 1000ms * Must have a home computer (desktop or laptop) and reliable internet access * Willing, able, and competent to provide informed consent * Normal cognitive abilities, able to understand written and oral instructions in English, and competent and responsible adults in order to complete the visual training at home, independently, as instructed, for several months. Exclusion: * Past or present eye disease interfering with visual acuity * BCVA worse than 20/40 in either eye * Damage to the dorsal Lateral Geniculate Nucleus * Diffuse whole brain degenerative processes * History of traumatic brain injury * Any other brain damage deemed by study staff to potentially interfere with training ability or outcome measures * Documented history of drug/alcohol abuse * Currently taking neuroactive medications which would impact training, as determined by PI * Presence of cognitive or seizure disorders * One-sided attentional neglect * Subjects who lack the competence or are otherwise unable to perform the visual training exercises as directed. Control Subjects (n = 50) Inclusion: * Between 21 and 80 years of age * Report no history of neurological disorder. * Competent and responsible, as determined by the Principal Investigator. Exclusion: * Presence of damage to the visual system * Presence of an active disease process involving their nervous system. * Cognitive or seizure disorders * Best corrected visual acuity worse than 20/40 in either eye * Presence of vision field loss from ocular disease or disorder
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Cortical blindness are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
University of Rochester Medical Center
RECRUITINGRochester, New York, 14642, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Intravenous tenecteplase for acute ischemic stroke within 4.5 to 6 hours of onset (EXIT-BT2): a prospective, randomized, open label, blinded endpoint, and multi-center study
- Emergency stroke unit for acute cerebrovascular events: a prospective, single-arm trial with a historical control group
- A multicenter, randomized, double-blind, placebo-controlled, parallel-group phase ⅱb/ⅲ clinical study to evaluate the efficacy and safety of XY03-EA tablets in the treatment of acute ischemic stroke
- AI may forecast stroke outcomes and guide recovery
- Robotic rehab may retrain the brain's sense of vertical after stroke
- Retraining the brain to see again: a new hope for Stroke-Related blindness